Clinical trials
Hepatitis B Infection clinical trials
Below are recruiting hepatitis b infection clinical trials, each written for real people, not researchers. We’re tracking 124 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06216470RecruitingPhase 2
Testing an antibody treatment for chronic hepatitis B
This study tests a new antibody treatment (VIR-3434) for chronic hepatitis B. It aims to see if the antibody can help your immune system control the virus, potentially allowing you to stop your current antiviral medication later.
Toronto, OntarioAges 18–65 - NCT07024641RecruitingPhase 1
Safety study of GIGA-2339 for chronic Hepatitis B
This study tests an experimental antibody (GIGA-2339) given as an infusion to people with chronic Hepatitis B. It aims to see if the drug is safe and how the body processes it, possibly helping to control the virus.
Chandler, ArizonaAges 18 years+ - NCT06966908Recruiting
Managing hepatitis B in non-specialty hospital settings
This study looks at how patients with chronic hepatitis B are managed when they visit non-liver clinics. It aims to improve care and may also include a survey about quality of life for those starting treatment.
Guangzhou, GuangdongAges Any age - NCT06680232RecruitingPhase 1
Gene therapy trial for chronic hepatitis B
This trial tests a gene therapy called PBGENE-HBV for people with chronic hepatitis B who are already on antiviral treatment. The goal is to see if it is safe and can help control the virus.
Boston, MassachusettsAges 18–70 - NCT06638320Recruiting
Hepatitis Delta Risk Study in Hepatitis B Patients
This study looks for hepatitis delta virus (a virus that only affects people with hepatitis B) in patients who have chronic hepatitis B. Researchers want to understand how common this co-infection is and which patients are at highest risk.
Hà Nội, Northern VietnamAges 16 years+ - NCT06513286RecruitingPhase 1/Phase 2
Therapeutic hepatitis B vaccine study using a two-part shot
This trial tests a new vaccine to treat chronic hepatitis B. It's for people who have been on antiviral medication for at least 6 months and still have a low level of the virus in their blood.
FrankfurtAges 18–70 - NCT04843852RecruitingPhase 1
Test vaccine added to hepatitis B treatment
This early-phase study tests whether a hepatitis B vaccine (with an added ingredient to boost the immune response) can safely help people with long-term hepatitis B who are already on antiviral therapy. It is mainly looking at safety and how the immune system responds.
Baltimore, MarylandAges 18 years+ - NCT05771402RecruitingPhase 2
Combination treatment aimed at clearing hepatitis B long-term
This Phase 2 study tests a combination treatment to help people with chronic hepatitis B stop having detectable hepatitis B surface antigen (called HBsAg). If successful, it may move you closer to a “functional cure,” meaning lower ongoing virus activity over time.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT05769816RecruitingPhase 2
Combination treatment aimed to cure chronic hepatitis B
This Phase 2 study tests a combination therapy to help people with chronic hepatitis B reach a “functional cure,” meaning the hepatitis B surface antigen (HBsAg) is lost for a sustained period. If you qualify, you’ll be closely monitored to see how well the treatment works and whether it’s safe for you.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT05390424Recruiting
Test dried blood spots for hepatitis and HIV
This study checks blood from a simple dried blood spot to screen for hepatitis B, hepatitis C, and HIV. It may help find infections early, which can allow earlier treatment.
AvranchesAges 18 years+ - NCT05051098Recruiting
Registry for people with hepatitis B infection
This study is a registry, meaning it collects health information from people living with hepatitis B rather than giving a new treatment. It may help researchers better understand different hepatitis B groups and outcomes over time.
HanoverAges 18 years+ - NCT03933384RecruitingPhase 4
Tenofovir alafenamide versus entecavir for chronic hepatitis B
This study compares two approved hepatitis B medicines—tenofovir alafenamide and entecavir—to see which works best for people with chronic hepatitis B. It may help improve control of the virus and support better long-term liver health.
Taichung, TaichungAges 20 years+ - NCT03826433RecruitingPhase 1
Study stem cell treatment for worsening hepatitis B cirrhosis
This Phase 1 study tests a stem cell product to see if it is safe and how it affects people with worsening hepatitis B-related cirrhosis. It may help researchers understand whether the treatment could improve liver function in this stage of illness.
Changsha, HunanAges 18–60 - NCT07709520RecruitingPhase 2
Testing a new hepatitis B treatment in adults
This trial tests a new treatment (GST-HG131&141 tablets) versus a placebo for people with chronic hepatitis B. It aims to see if the treatment can better control the virus in those already on stable therapy.
BeijingAges 35–65 - NCT07635186RecruitingPhase 2
AHB-137 injection for treatment-naïve chronic hepatitis B
This study tests a new injection called AHB-137 in people with chronic hepatitis B who have never received antiviral treatment. The goal is to see if it can help reduce the hepatitis B virus in the body and improve liver health.
Beijing, Beijing MunicipalityAges 18–65 - NCT07630727RecruitingPhase 2
AHB-171 treatment for chronic hepatitis B
This study tests whether a new drug called AHB-171 can help treat chronic hepatitis B (a long-term liver infection). You would receive the drug by injection under your skin and be monitored to see if it helps reduce the hepatitis B virus and improves liver health.
Beijing, Beijing MunicipalityAges 18–65 - NCT02883647Recruiting
Stopping antiviral treatment in chronic hepatitis B
This trial studies what happens after stopping long-term hepatitis B antiviral medicine in people whose virus has stayed controlled. It also follows patients over time to see how well they remain stable and safe after stopping.
Guangzhou, GuangdongAges 18–65 - NCT06263959RecruitingPhase 2
Testing a new hepatitis B pill (GST-HG131) for chronic HBV
This study tests a new drug, GST-HG131, for people with chronic hepatitis B who are already on stable treatment. It aims to see if the drug is safe and reduces the virus further.
BeijingAges 35–65 - NCT07307586RecruitingPhase 3
Azvudine for new hepatitis B patients
This study tests a new pill (azvudine) to see if it can cure chronic hepatitis B in people who have never been treated before. It is for those with active infection and elevated liver enzymes.
Zhengzhou, HenanAges 18–65 - NCT06887036RecruitingPhase 2
Methylene blue for chronic inactive hepatitis B
This trial tests whether a medication called methylene blue can help lower the amount of hepatitis B virus in people with a chronic but inactive infection. It may be an option for people whose virus levels are stable but not fully controlled.
Lugano, Canton TicinoAges 18–79 - NCT06876467Recruiting
Study of immune response to hepatitis B vaccine
This study looks at how your body's cells respond after getting a hepatitis B vaccine. It may help researchers understand how well the vaccine works.
ParisAges 18 years+ - NCT06154278RecruitingPhase 2
Testing imdusiran for chronic hepatitis B
This trial tests an injected medication called imdusiran (AB-729) to see how it affects the immune system in people with chronic hepatitis B. It is for people who are already stable on oral antivirals and want to try a new approach to possibly control the virus better.
Baltimore, MarylandAges 18 years+ - NCT06425341RecruitingPhase 2
Test injection to keep hepatitis B suppressed
This Phase 2 trial studies an injection (HRS-5635), either alone or with other medicines, to see if it is safe and helps keep chronic hepatitis B under control. It is for people who are already on standard hepatitis B antivirals and have low or undetectable viral levels.
Guangzhou, GuangdongAges 18 years+ - NCT02699736Enrolling by invitation
HIV and hepatitis C study in European adults
This study follows people living with HIV who also have hepatitis C antibodies, to better understand how HIV and hepatitis C affect health over time. You may be able to join if you meet the age and enrollment requirements, even if your hepatitis C virus level is currently undetectable.
Buenos AiresAges 16 years+
Hear when a new Hepatitis B Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatitis b infection?
- Yes. Clin2 currently lists 124 recruiting hepatitis b infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatitis b infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatitis b infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.